Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass
© Robciuc et al; licensee BioMed Central Ltd. 2010
- Received: 5 May 2010
- Accepted: 9 June 2010
- Published: 9 June 2010
phospholipid transfer protein (PLTP) plays important roles in lipoprotein metabolism and atherosclerosis and is expressed by macrophages and macrophage foam cells (MFCs). The aim of the present study was to determine whether the major protein from HDL, apoA-I, affects PLTP derived from MFCs.
as cell model we used human THP-1 monocytes incubated with acetylated LDL, to generate MFC. The addition of apoA-I to the cell media increased apoE secretion from the cells, in a concentration dependent fashion, without affecting cellular apoE levels. In contrast, apoA-I had no effect on PLTP synthesis and secretion, but strongly induced the PLTP activity in the media. ApoA-I also increased phospholipid transfer activity of PLTP isolated from human plasma. This effect was dependent on apoA-I concentration but independent on apoA-I lipidation status. ApoE, ApoA-II and apoA-IV, but not immunoglobulins or bovine serum albumin, also increased PLTP activity. We also report that apoA-I protects PLTP from heat inactivation.
apoA-I enhances the phospholipid transfer activity of PLTP secreted from macrophage foam cells without affecting the PLTP mass.
- High Density Lipoprotein
- Reverse Cholesterol Transport
- Macrophage Foam Cell
- Human apoE
- PLTP Activity
Atherosclerosis is an inflammatory disorder in the artery wall caused by the accumulation of atherogenic lipoproteins such as low density lipoproteins (LDL) and triglyceride rich remnant lipoproteins. In the artery wall these lipoproteins are modified and taken up by macrophages. This sterol loading of the macrophages promotes the formation of macrophage foam cells (MFCs) essential constituents of human atherosclerotic lesions . Currently, major efforts are made to develop therapies that will promote removal of cholesterol from lesion foam cells and lead to regression of the atherosclerotic process . Animal studies have shown that high density lipoproteins (HDL) can promote the removal of cholesterol from the arterial wall and transport it to the liver for excretion in a process called reverse cholesterol transport (RCT) . In addition to RCT, HDL also has several other protective functions such as antioxidant, antiinflammatory, vasodilating and antithrombotic properties that contribute to the strong independent inverse relationship with atherosclerotic cardiovascular disease .
Phospholipid transfer protein (PLTP) is expressed by macrophages and the expression levels are increased in MFCs due to LXR activation [4–6]. Bone marrow transplantation studies in mice using PLTP deficient macrophages gave conflicting results, and this treatment either decreased  or increased atherosclerosis . Mechanisms by which macrophage PLTP may be protective in atherogenesis involves the stabilization of ATP-binding cassette transporter A1 (ABCA1) and stimulation of cholesterol efflux [9, 10], however, a recent study suggests that elevation of PLTP in macrophage does not affect RCT . Furthermore, PLTP expression by macrophages results in atherogenic effects on plasma lipids and increased atherosclerotic lesion size .
Interestingly, it was shown that HDL levels are an important determinant of PLTP levels and it was further suggested that HDL might play a role in the stabilization of PLTP [13, 14]. To date, no detailed studies addressing the effect of apoA-I on PLTP expression and secretion from human macrophages have been reported.
In the present study we have investigated the effect of exogenous human apoA-I on the synthesis and secretion of PLTP from human macrophage foam cells.
Cell culture, lipid loading and pharmacological treatments
Human THP-1 monocytes were purchased from the American Type Culture Collection (ATCC, Manassas, VA). The monocytes were grown and maintained in RPMI 1640 medium containing 10% (v/v) FBS, 10 mM Hepes, pH 7.4, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C under 5% CO2 in a humidified incubator. To differentiate the monocytes into macrophages, the cells were plated onto 24-well plates and treated with 100 nM phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO) in the growth medium for 72 h prior to the experiment. The macrophages were loaded by incubating them in the presence of 25 μg of protein/well of acetylated LDL (AcLDL) in RPMI 1640 supplemented with 5% (v/v) fetal bovine lipoprotein deficient serum (LPDS), 10 mM Hepes, pH 7.4, and penicillin/streptomycin for 48 h. ApoE protein and PLTP mRNA, protein and activity levels were assessed 24 h after incubation in the presence or absence of apoA-I. The viability and attachment of the cells were carefully evaluated by light microscopy and protein measurements and no cytotoxic effects could be observed.
SDS-PAGE and Immunoblot Analysis
Equivalent amounts of protein from the cell lysate and medium were subjected to Western blot analysis. Medium was concentrated 50-fold for the detection of apoE and PLTP. To detect apoE we used a monoclonal antibody raised against the human apoE or a horseradish peroxidase (HRP)-conjugated polyclonal antibody specific for human apoE (DAKO, Denmark). For PLTP detection we used a mouse monoclonal antibody (Mab59) or a rabbit polyclonal antibody raised against purified human plasma PLTP. Cellular actin was detected using a specific rabbit polyclonal antibody (Santa Cruz).
Human apoE was detected by ELISA as described previously  with some modifications. Briefly, we used a polyclonal rabbit antibody (R107) as a capture antibody to coat 96-well plates. As a detection antibody we used a HRP-conjugated polyclonal antibody specific for human apoE (DAKO, Denmark). Standard curve was prepared using a standardized serum (Daichi, Japan).
Gene expression analyses
PLTP mRNA levels were measured by real time PCR using as forward primer 5'-ACGCAGGGACGGTCCTGCTC-3' and as reverse primer 5'-CTCATTGAGCATGGGCATCACCCC-3' . Cultured cells were homogenized in RLT buffer (Qiagen, Valencia, CA) and total RNA was isolated with RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. The total RNA (2 μg) was reverse-transcribed by using Superscript II (Invitrogen, Carlsbad, CA) and random hexamer primers (Applied Biosystems, Foster City, CA). Samples were amplified in triplicate for PLTP and two housekeeping genes, GAPDH and 18S rRNA, on a 7000 Sequence Detection System (Applied Biosystems), using a SYBR-green kit (Applied Biosystems).
Purification of PLTP from human plasma
PLTP was purified from human plasma according to Marques-Vidal et al. . Briefly, the human plasma fractions, eluted from Butyl-Toyopearl 650(M) column, containing PLTP activity were combined and applied to a first heparin-sepharose column. After extensive washing with the equilibration buffer, PLTP activity was eluted with 25 mM Tris-HCl buffer, pH 7.40, containing 1 mM EDTA and 1.0 M NaCl. The fractions containing PLTP activity were combined, dialysed against 25 mM Tris-HCl buffer, pH = 7.40, containing 1 mM EDTA, and applied to a Mono Q HR 5/5 column, attached to a Merck HPLC system. The column was eluted with a linear NaCl gradient (0-0.5 M) prepared in equilibration buffer. The fractions containing PLTP activity were combined, dialysed against 25 mM Tris-HCl buffer, pH 7.40, containing 1 mM EDTA and then applied on a second heparin-sepharose column (Hi-Trap, 1 ml total volume, Pharmacia, Upsala, Sweden). The column was then eluted with a linear NaCl gradient (0-0.5 M). Active fractions from the Hi-Trap column were pooled and applied to a hydroxylapatite column (2 ml total volume) previously equilibrated with 1 mM Na-phosphate buffer, pH 6.80, containing 150 mM NaCl. PLTP was eluted with a linear Na-phosphate gradient (1-500 mM). PLTP activity eluted at a phosphate concentration of 125-150 mM. PTLP activity ranged between 2000 and 6000 nmol phospholipid transferred/h/ml depending on the preparation and was devoid of H-TGL, LCAT, phospholipase and CETP activity.
PLTP activity was measured using a radiometric method as previously described . Cholesterol loaded macrophage media was 5-fold concentrated by ultrafiltration and washed twice with PLTP activity assay buffer before the activity was measured.
For apoA-I lipidation we used increasing amounts of L-α-Phosphatidylcholine (Sigma-Aldrich, St. Louis, MO). The molar ratio of the proteoliposomes, apoA-I:PC:CHOL, was as follow: 1:50:0, 1:50:7, 1:100:0, 1:100:7, 1:150:0 and 1:150:7. PC and CHOL were dried under nitrogen at room temperature in glass tubes and resuspended in the assay buffer (10 mM Tris-HCl, 1 mM EDTA, 140 mM NaCl, pH 7.4). ApoA-I was added to the mixture at a concentration of 1 mg/ml. After the addition of Na-cholate the samples were mixed gently avoiding foaming followed by 20 minutes incubation at 24°C in a water bath with gentle shaking. Finally the samples were dialyzed against assay buffer for 20-40 hours and stored at + 4°C.
PLTP synthesized by macrophage and MFCs has been associated with the development of atherosclerosis. In the current study we investigated the effect of apoA-I on PLTP secreted from MFC.
Our results confirm existing data which show that apoA-I strongly stimulates apoE secretion from macrophages, an effect that is likely to contribute to the antiatherogenic potential of HDL. Interestingly, the enhancement of apoE secretion induced by apoA-I is concentration dependent, but even at levels as high as 80 μg/ml a saturation of the system could not be demonstrated. This suggests that the system capacity is very high and can have important consequences in MFCs physiology as well as in plasma lipoprotein metabolism.
PLTP secreted by macrophages contributes significantly to total plasma phospholipid transfer activity . The plasma PLTP pool derived from macrophages has most probably a major impact on plasma lipoprotein metabolism and atherogenesis. In the present study we demonstrate that apoA-I does not affect PLTP secretion from macrophages but instead increases PLTP facilitated phospholipid transfer activity. The induction of phospholipid transfer is due to a direct effect of apoA-I on PLTP since the incubation of purified PLTP in the presence of apoA-I resulted in an effect similar to that observed with macrophage derived PLTP. These in vitro observations suggest that this effect most probably is valid for PLTP secreted from other tissues. Indeed, the PLTP activity in ABCA1 deficiency, that results in very low levels of apoA-I and HDL in plasma, is significantly reduced [13, 14]. The effect we report here is specific not only for apoA-I since an increase of PLTP activity was also observed following incubation in the presence of other apolipoproteins such as apoA-II, apoA-IV and apoE. This suggests that PLTP requires interactions with proteins containing amphipathic α-helix domains for proper lipid transfer activity. Interestingly, similar structural characteristics are needed for the induction of apoE secretion from macrophages .
It is well known that PLTP is associated in plasma with HDL  and the particles containing PLTP are highly variable regarding the phospholipid transfer capacity . It is not clear yet what is the determining factor for the differences in the PLTP activity and this remains to be established [24, 25]. Although the interaction of PLTP with lipoprotein surfaces is an obligatory component of lipid transfer, so far, it was not clearly demonstrated that apoA-I and HDL can actually enhance PLTP activity.
It was recently reported that macrophage PLTP deficiency causes a significant reduction of apoE secretion in vivo . The mechanism behind this observation is not known but it may involve the stabilizing effect of PLTP on ABCA1, known to be responsible for basal apoE secretion . A second possibility is that PLTP could mediate HDL induced secretion of apoE from macrophages. Our observations, that apoA-I does not affect the synthesis and secretion of PLTP from macrophages and that increased PLTP activity in macrophage media, by addition of exogenous active PLTP, do not increase apoE secretion from macrophages, are indirect evidence that the first hypothesis is more likely.
In summary, we have demonstrated that, in cholesterol loaded macrophages, apoA-I does not affect PLTP synthesis or secretion but increases PLTP mediated phospholipid transfer activity. The same was observed with purified plasma PLTP and the effect was independent on apoA-I lipidation status and could be demonstrated by other proteins containing amphipathic α-helix domains. We also provide evidence that the apoA-I induced apoE secretion from macrophages and the enhancement of PLTP activity by apoA-I are unrelated phenomena.
The authors would like to express gratitude to Acad. Maya Simionescu for facilitating this collaborative study and Sari Nuutinen for excellent technical assistance. This study was supported by the Research Council for the Health, Academy of Finland, Grants 114484 and 132629, Ministry for Education, Research, Youth and Sport, Romania, Grant 1220/2008, Finska Läkaresällskape and Magnus Ehrnrooth Foundation.
- Rocha VZ, Libby P: Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009, 6 (6): 399-409. 10.1038/nrcardio.2009.55View ArticlePubMedGoogle Scholar
- Duffy D, Rader DJ: Update on strategies to increase HDL quantity and function. Nat Rev Cardiol. 2009, 6 (7): 455-463. 10.1038/nrcardio.2009.94View ArticlePubMedGoogle Scholar
- Escola-Gil JC, Rotllan N, Julve J, Blanco-Vaca F: In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis. 2009, 206 (2): 321-327. 10.1016/j.atherosclerosis.2008.12.044View ArticlePubMedGoogle Scholar
- Laffitte BA, Joseph SB, Chen M, Castrillo A, Repa J, Wilpitz D, Mangelsdorf D, Tontonoz P: The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol. 2003, 23 (6): 2182-2191. 10.1128/MCB.23.6.2182-2191.2003PubMed CentralView ArticlePubMedGoogle Scholar
- Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, Ehnholm C, Curtiss LK: Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res. 2003, 44 (8): 1453-1461. 10.1194/jlr.M200281-JLR200View ArticlePubMedGoogle Scholar
- O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, Marcovina S, Wight TN, Chait A, Albers JJ: Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation. 2003, 108 (3): 270-274. 10.1161/01.CIR.0000079163.97653.CDView ArticlePubMedGoogle Scholar
- Vikstedt R, Ye D, Metso J, Hildebrand RB, Van Berkel TJ, Ehnholm C, Jauhiainen M, Van Eck M: Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler Thromb Vasc Biol. 2007, 27 (3): 578-586. 10.1161/01.ATV.0000254815.49414.beView ArticlePubMedGoogle Scholar
- Valenta DT, Ogier N, Bradshaw G, Black AS, Bonnet DJ, Lagrost L, Curtiss LK, Desrumaux CM: Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler Thromb Vasc Biol. 2006, 26 (7): 1572-1578. 10.1161/01.ATV.0000225700.43836.aeView ArticlePubMedGoogle Scholar
- Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ: Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem. 2003, 278 (52): 52379-52385. 10.1074/jbc.M310695200View ArticlePubMedGoogle Scholar
- Lee-Rueckert M, Vikstedt R, Metso J, Ehnholm C, Kovanen PT, Jauhiainen M: Absence of endogenous phospholipid transfer protein impairs ABCA1-dependent efflux of cholesterol from macrophage foam cells. J Lipid Res. 2006, 47 (8): 1725-1732. 10.1194/jlr.M600051-JLR200View ArticlePubMedGoogle Scholar
- Samyn H, Moerland M, van Gent T, van Haperen R, Grosveld F, van Tol A, de Crom R: Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Atherosclerosis. 2009, 204 (2): 429-434. 10.1016/j.atherosclerosis.2008.10.020View ArticlePubMedGoogle Scholar
- van Haperen R, Samyn H, Moerland M, van Gent T, Peeters M, Grosveld F, van Tol A, de Crom R: Elevated expression of phospholipid transfer protein in bone marrow derived cells causes atherosclerosis. PLoS One. 2008, 3 (5): e2255- 10.1371/journal.pone.0002255PubMed CentralView ArticlePubMedGoogle Scholar
- Oka T, Yamashita S, Kujiraoka T, Ito M, Nagano M, Sagehashi Y, Egashira T, Nanjee MN, Hirano K, Miller NE: Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia. J Lipid Res. 2002, 43 (8): 1236-1243.PubMedGoogle Scholar
- Samyn H, Moerland M, van Gent T, van Haperen R, van Tol A, de Crom R: Reduction of HDL levels lowers plasma PLTP and affects its distribution among lipoproteins in mice. Biochim Biophys Acta. 2009, 1791 (8): 790-796.View ArticlePubMedGoogle Scholar
- Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C: PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J Lipid Res. 2003, 44 (9): 1698-1704. 10.1194/jlr.M300059-JLR200View ArticlePubMedGoogle Scholar
- Marques-Vidal P, Jauhiainen M, Metso J, Ehnholm C: Transformation of high density lipoprotein 2 particles by hepatic lipase and phospholipid transfer protein. Atherosclerosis. 1997, 133 (1): 87-95. 10.1016/S0021-9150(97)00120-2View ArticlePubMedGoogle Scholar
- Jauhiainen M, Ehnholm C: Determination of human plasma phospholipid transfer protein mass and activity. Methods. 2005, 36 (2): 97-101. 10.1016/j.ymeth.2004.11.006View ArticlePubMedGoogle Scholar
- Pussinen PJ, Jauhiainen M, Metso J, Pyle LE, Marcel YL, Fidge NH, Ehnholm C: Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J Lipid Res. 1998, 39 (1): 152-161.PubMedGoogle Scholar
- Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC: Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler Thromb Vasc Biol. 2007, 27 (1): 190-196. 10.1161/01.ATV.0000249721.96666.e5View ArticlePubMedGoogle Scholar
- Tollefson JH, Ravnik S, Albers JJ: Isolation and characterization of a phospholipid transfer protein (LTP-II) from human plasma. J Lipid Res. 1988, 29 (12): 1593-1602.PubMedGoogle Scholar
- Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T, Sviridov D, Fu Y, Sullivan D, Burnett JR: Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem. 2004, 279 (25): 25966-25977. 10.1074/jbc.M401177200View ArticlePubMedGoogle Scholar
- Lagrost L, Desrumaux C, Masson D, Deckert V, Gambert P: Structure and function of the plasma phospholipid transfer protein. Curr Opin Lipidol. 1998, 9 (3): 203-209. 10.1097/00041433-199806000-00004View ArticlePubMedGoogle Scholar
- Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, Miller NE, Metso J, Olkkonen VM, Ehnholm C: Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res. 2000, 41 (10): 1651-1657.PubMedGoogle Scholar
- Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, Ehnholm C: Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem. 2002, 277 (18): 15413-15418. 10.1074/jbc.M112247200View ArticlePubMedGoogle Scholar
- Cheung MC, Albers JJ: Active plasma phospholipid transfer protein is associated with apoA-I- but not apoE-containing lipoproteins. J Lipid Res. 2006, 47 (6): 1315-1321. 10.1194/jlr.M600042-JLR200View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.